192 related articles for article (PubMed ID: 21712498)
61. Rosuvastatin calcium.
Quirk J; Thornton M; Kirkpatrick P
Nat Rev Drug Discov; 2003 Oct; 2(10):769-70. PubMed ID: 14579811
[No Abstract] [Full Text] [Related]
62. Rosuvastatin: efficacy, safety and clinical effectiveness.
Soran H; Durrington P
Expert Opin Pharmacother; 2008 Aug; 9(12):2145-60. PubMed ID: 18671469
[TBL] [Abstract][Full Text] [Related]
63. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
64. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
[TBL] [Abstract][Full Text] [Related]
65. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
66. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive.
Simonson SG; Martin PD; Warwick MJ; Mitchell PD; Schneck DW
Br J Clin Pharmacol; 2004 Mar; 57(3):279-86. PubMed ID: 14998424
[TBL] [Abstract][Full Text] [Related]
67. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
Kawashiri MA; Yamagishi M; Sakamoto T; Takayama T; Hiro T; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
Cardiovasc Ther; 2013 Dec; 31(6):335-43. PubMed ID: 23409830
[TBL] [Abstract][Full Text] [Related]
68. [Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor].
Bousquet P; Gayet JL
Therapie; 2003; 58(2):113-21. PubMed ID: 12942850
[TBL] [Abstract][Full Text] [Related]
69. Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study.
Riccioni G; Bazzano LA; Bucciarelli T; Mancini B; di Ilio E; D'Orazio N
Expert Opin Pharmacother; 2008 Oct; 9(14):2403-8. PubMed ID: 18778179
[TBL] [Abstract][Full Text] [Related]
70. Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin.
Yu CY; Campbell SE; Zhu B; Knadler MP; Small DS; Sponseller CA; Hunt TL; Morgan RE
Curr Med Res Opin; 2012 Feb; 28(2):187-94. PubMed ID: 22149769
[TBL] [Abstract][Full Text] [Related]
71. The effects of rosuvastatin on the serum cortisol, serum lipid, and serum mevalonic acid levels in the healthy Indian male population.
Wani TA; Samad A; Tandon M; Saini GS; Sharma PL; Pillai KK
AAPS PharmSciTech; 2010 Mar; 11(1):425-32. PubMed ID: 20300897
[TBL] [Abstract][Full Text] [Related]
72. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
Ofotokun I; Acosta EP; Lennox JL; Pan Y; Easley KA
Pharmacotherapy; 2008 Jan; 28(1):74-81. PubMed ID: 18154477
[TBL] [Abstract][Full Text] [Related]
73. Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease.
Abe M; Maruyama N; Yoshida Y; Ito M; Okada K; Soma M
Endocr J; 2011; 58(8):663-74. PubMed ID: 21670545
[TBL] [Abstract][Full Text] [Related]
74. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
Cattaneo D; Gervasoni C; Cozzi V; Baldelli S; Fucile S; Meraviglia P; Landonio S; Boreggio G; Rizzardini G; Clementi E
Pharmacol Res; 2012 Feb; 65(2):198-203. PubMed ID: 21958880
[TBL] [Abstract][Full Text] [Related]
75. Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.
Ferdinand KC
Expert Opin Pharmacother; 2005 Sep; 6(11):1897-910. PubMed ID: 16144509
[TBL] [Abstract][Full Text] [Related]
76. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
Sekar V; Spinosa-Guzman S; De Paepe E; Stevens T; Tomaka F; De Pauw M; Hoetelmans RM
Clin Pharmacokinet; 2010 May; 49(5):343-50. PubMed ID: 20384396
[TBL] [Abstract][Full Text] [Related]
77. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
78. Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
Singh S; Willig JH; Mugavero MJ; Crane PK; Harrington RD; Knopp RH; Kosel BW; Saag MS; Kitahata MM; Crane HM
Clin Infect Dis; 2011 Feb; 52(3):387-95. PubMed ID: 21189273
[TBL] [Abstract][Full Text] [Related]
79. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
[TBL] [Abstract][Full Text] [Related]
80. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
